Why Two Specialists Can Look at the Same MCAS Symptoms and Reach Opposite Conclusions
One clinician draws your blood in the middle of a flare, watches your tryptase climb past your own resting baseline, and writes mast cell activation syndrome in your chart before the appointment ends. Months later, a second clinician reviews the same history, sees a resting tryptase sitting inside the normal range, and tells you the diagnosis doesn't hold up. Nothing about your body changed between those two visits. The framework did.
This article is for educational and organizational purposes only. It is not medical advice.
Two Different Questions About the Same Number
There are two credible ways to decide whether a lab result means anything.
One method only counts if the test happened at the exact moment you're checking for — like a traffic camera that only proves congestion if it was filming during rush hour; an empty bridge at 3 a.m. tells you nothing. The other uses a fixed threshold: cross it, and it counts, no matter when you check.
Mast cell activation syndrome's two diagnostic frameworks split along almost this line. Consensus-1, or the ECNM-AIM criteria, asks for a tryptase rise measured against your own resting baseline, drawn within about four hours of an active episode — if nobody drew blood during that window, the criterion isn't failed, it's untested. Consensus-2 asks whether any marker in a wider panel — tryptase, but also chromogranin A, heparin, and prostaglandin and histamine metabolites — sits above the general reference range, read in the context of your symptoms, regardless of timing.
So two clinicians can read an identical lab report and answer two different questions: did your number move at the right moment, or is your number high right now. A resting tryptase inside the normal range answers only the second question. That gap — not disbelief, not carelessness — is where a lot of these conflicting verdicts come from.
What Each Framework Actually Requires
The two frameworks differ in three concrete ways.
| Consensus-1 / ECNM-AIM | Consensus-2 | |
|---|---|---|
| Symptom criteria | About 18 specific symptoms, mostly shaped like episodic, anaphylaxis-type events | Roughly 153 symptoms across 15 organ systems; chronic, fluctuating patterns are included |
| Lab evidence | Tryptase rise of at least 120% + 2 ng/mL over your own baseline, drawn within 4 hours of an episode | Any marker in a broader mediator panel above the general reference range, read in clinical context |
| Treatment response | Required — at least partial response to mast-cell-directed medication is an essential criterion | Supportive, not required — useful evidence, but the diagnosis doesn't depend on it |
Both frameworks agree on the basics: symptoms must involve at least two organ systems, recur, and not be better explained by another condition. The disagreement isn't whether MCAS exists — it's how wide a net counts as accurate.
Fifteen Years, No Winner
Consensus-2 traces to a 2011 proposal from Molderings and colleagues; Afrin and colleagues formally named and defended it as "consensus-2" in 2020. The stricter ECNM-AIM approach followed. Both have been reaffirmed since — most recently in a June 2026 paper defending consensus-2 and a November 2025 paper endorsing the stricter framework. Neither side has backed down.
What's notable is what the 2020 consensus-2 paper admits about the field itself: there has not yet been a single study comparing the validity of either proposal against the other. Six years later, that's still true.
"There has not yet been even a single study comparing the validity of any one proposal for MCAS diagnostic criteria against any other such proposal."
— Afrin et al., 2020
Why Reasonable People Land on Both Sides
The case for stricter criteria isn't about doubting patients — it's a documented worry. A 2025 Stanford study (Solomon and Khatri) compared both frameworks' symptom lists and found the broader consensus-2 list overlaps heavily with dozens of unrelated conditions, while the stricter list points to a narrower, more consistent set. A separate 2024 study found only 4.4 percent of 703 patients referred for suspected mast cell disorders actually met strict criteria. A wrong label can mean the true condition never gets investigated.
The case for broader criteria is just as real. Mediators fluctuate quickly and often normalize before a patient reaches a lab, so strict testing can come back clean in someone with substantial clinical evidence. The same 2024 review that raises the overdiagnosis concern also states, in the same paper, that a normal tryptase does not rule out mast cell involvement — written by researchers who don't fully agree with each other, a fair summary of where the field stands.
What This Looks Like From the Patient's Side
A 2024 UK survey by Mast Cell Action, gathering responses from 130 people with suspected or confirmed MCAS, shows some of this in practice. Among respondents with a confirmed diagnosis, tryptase was the most commonly ordered test — and every reported result came back normal. Twelve people were diagnosed on symptoms and treatment response alone, no biomarker testing involved — a consensus-2-shaped diagnosis, reached without the tryptase question ever needing to resolve. Satisfaction with the diagnostic process was low: 61 percent described themselves as dissatisfied or very dissatisfied.
"When having emergency admissions to hospital, I was often not believed or treated with the correct medication."
— Mast Cell Action UK survey, 2024
None of this means a normal tryptase settles anything, or that an abnormal one does either. It means two defensible frameworks are being applied to the same condition, and which one your clinician trusts can matter as much as anything in your chart. That isn't a reason to distrust either doctor — it's a reason to know the disagreement exists before it happens to you.
Does this mean MCAS isn't a real condition?
No. Both frameworks agree MCAS exists and describe the same underlying biology — mast cells releasing chemical mediators in a way that produces symptoms across organ systems. The disagreement is where to draw the line for confirming it in one person, not whether the condition is real.
How do I know which framework my clinician is using?
Stricter-framework clinicians want tryptase drawn close to an episode and compared to your resting level, with medication response required. Broader-framework clinicians order a wider mediator panel and treat medication response as supportive, not mandatory.
If my tryptase is normal, does that rule out MCAS?
Not on its own. A normal resting tryptase mainly tells you that number wasn't elevated at the moment it was drawn — it doesn't confirm or exclude ongoing mast cell activity, especially if the sample wasn't taken during or shortly after a flare.
What's useful to have ready if I'm getting a second opinion?
Records help either framework: when symptoms happened, which organ systems were involved, what testing was done and when relative to symptoms, and how you responded to any medication trial.
Does tracking my symptoms replace seeing a doctor?
No. Personal tracking or record-keeping can help you organize what you've noticed and communicate it more clearly, but it does not diagnose, treat, or replace an evaluation from a qualified healthcare professional.
What should I do if my symptoms are getting worse?
Contact a healthcare professional. This article is educational and does not substitute for medical evaluation, especially for new, worsening, or severe symptoms.
Sources:
Afrin LB, et al. Diagnosis (Berlin), 2026 — consensus-2 criteria at six years.
Afrin LB, et al. Diagnosis (Berlin), 2020 — the "consensus-2" proposal.
Solomon BD, Khatri P. Journal of Allergy and Clinical Immunology, 2025 — symptom-specificity comparison.
Lee E, Picard M. Allergy, Asthma & Clinical Immunology, 2025 — ECNM-AIM diagnostic approach.
Molderings GJ, et al. Journal of Hematology & Oncology, 2011 — original consensus-2 criteria.
Zaghmout T, et al. JACI: In Practice, 2024 — prevalence among 703 referred patients.
Castells M, et al. Journal of Allergy and Clinical Immunology, 2024 — current understanding and research needs.
Kelly L, Gotru S, Costa J. Mast Cell Action, UK, 2024 — patient survey on diagnosis and management.
